Eli Lilly & Company (Lilly) is a global pharmaceutical company, developing therapies for various diseases.
Lilly was first company to mass-produce penicillin and was also, one of the first to produce human insulin using rDNA technology. Also, Presently Lilly is the world’s largest manufacturer and distributor of psychiatric medications.
In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Pirtobrutinib / LOXO-305 | BTK | III | Mantle-Cell Lymphoma | NCT04662255 | Small Molecule |
| III | Chronic Lymphocytic Leukemia | NCT04666038 | |||
| Small Lymphocytic Lymphoma | |||||
| LY3484356 | SERD | I | Metastatic Breast Cancer | NCT04188548 | Small Molecule |
| Endometrial Cancer | |||||
| LY3475070 | CD73 | I | Advanced Cancer | NCT04148937 | Small Molecule |
| LY3295668 | Aur A Kinase | I | Neuroblastoma | NCT04106219 | Small Molecule |
| LY3410738 | IDH1 | I | Advanced Solid Tumors | NCT04521686 | Small Molecule |
| Advanced Hematologic Malignancies | NCT04603001 |
Eli Lilly Active Oncology Pipeline Drug Description
- Pirtobrutinib (LOXO-305) is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma.
- LY3484356 is a novel, oral selective estrogen-receptor degrader (SERD) in development against advanced ER+ breast cancer and endometroid endometrial cancer.
- LY3475070 is an oral, selective, noncompetitive inhibitor of CD73. In preclinical xenograft models,
- LY3475070 demonstrates reduction of adenosine in tumor tissue. In PBMCs, LY3475070 rescues adenosine-mediated suppression of T-cell proliferation and cytokine secretion.
- LY3295668 is highly selective Aurora A kinase inhibitor that targets cell-cycle dependency of sensitive tumors.
- Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation. Defects in segregation can cause genetic instability, a condition highly associated with the formation of tumors. Aurora kinases—Aurora A, Aurora B, and Aurora C—are key mitotic regulators required for genome stability and are frequently overexpressed in cancerous tumors.
- LY3410738 is a potent, selective, and covalent inhibitor of mutant IDH1 that has been shown in vitro and in vivo to rapidly inactivate mutant IDH1 and inhibit 2-HG production without impacting wild-type IDH1.8.
,
Page 2 of 2
